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ABSTRACT 
 
Estradiol-17β lowers blood pressure and dilates arteries. Genistein and daidzein are plant-
derived estrogens which originate mainly from soybean. Genistein and daidzein have been 
shown to lower serum cholesterol values, but their influence on other cardiovascular risk 
factors is still mainly unclear. The present series of studies was carried out to investigate 
the effects of genistein and daidzein on arterial tone and blood pressure, and to compare 
these effects with those of estradiol-17β. The study was focused on the following 
mechanisms of action of genistein and daidzein: gender, endothelium, potassium channels 
(K+ channels), estrogen receptors (ERs), and the inhibition of tyrosine kinases. Male, 
female and ovariectomized (OVX) normotensive Wistar rats, and male, female and OVX 
spontaneously hypertensive rats (SHR) were used. 
 
In the rat mesenteric arteries, estradiol-17β, genistein and daidzein induced relaxation 
gender- and endothelium-independently, estradiol-17β being the most potent relaxant and 
daidzein the weakest. Tamoxifen, an antagonist of the estrogen receptor α (ERα), did not 
inhibit estradiol-17β-, genistein- or daidzein-induced relaxations. Estradiol-17β- and 
daidzein-induced relaxations were inhibited by iberiotoxin (IbTX), an inhibitor of large 
conductance KCa channels, and by apamin, an inhibitor of small conductance KCa channels. 
Genistein-induced relaxation was also inhibited by IbTX, but not by apamin. 
 
In the ex vivo studies, mesenteric arterial contractility was more prevalent among males 
and OVX normotensive rats. The five-week soy protein supplementation had no effect on 
the contractions in either male or female SHRs. 
 
The two-day low-dose genistein (2.5 mg/kg/d) treatment attenuated renal arterial 
contractility in OVX SHRs, but the estradiol-17β (25 µg/kg/d) and the high-dose genistein 
(25 mg/kg/d) treatments did not. The two-week treatments had no effect on renal arterial 
contractility in OVX SHRs. The two-day low-dose genistein treatment reduced tyrosine 
phosphorylation in aortic smooth muscle cells of OVX SHRs, whereas the two-day 
treatments of estradiol-17β and high-dose genistein, as well as the two-week treatments of 
low-dose genistein, high-dose genistein or estradiol-17β, did not alter the tyrosine 
phosphorylation. 
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Male gender and OVX in normotensive rats decreased endothelium-independent 
relaxations, whereas the soy protein supplementation in SHRs, the low- (2.5 mg/kg/d) and 
the high-dose (25 mg/kg/d) genistein, and the estradiol-17β (25 µg/kg/d) treatments in 
OVX SHRs had no effect on either endothelium-dependent or –independent arterial 
relaxations. 
 
A five-week supplementation with soy protein, rich in genistein and daidzein, attenuated 
the development of hypertension in SHRs compared to a casein-based diet. The two-week 
estradiol-17β, and the low-dose or high-dose genistein treatments had no effect of the 
development of hypertension in OVX SHRs. 
 
From the present results it can be concluded that the plant-derived estrogens genistein 
and daidzein have relaxing effects similar to estradiol-17β on arterial smooth muscle in 
rats in vitro. These relaxations are independent of ERα, endothelium and gender, but are 
related to the activation of KCa channels. The tyrosine kinase inhibition of genistein also 
plays a role in genistein-induced alterations in arterial tone. The soy protein, rich in 
genistein and daidzein, has an attenuating effect on the development of hypertension in 
SHRs. The possible role of genistein and daidzein as alternatives to estradiol-17β in 
protection against cardiovascular diseases remains to be clarified in clinical studies. 
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1. INTRODUCTION 
 
Plant-derived estrogens are plant substances that are structurally or functionally similar to 
estradiol-17β or that produce an estrogenic effect (for review, see Fowler 1983). Plant-
derived estrogens bind competitively to both estrogen α (ERα) and estrogen β (ERβ) 
receptors and activate them (Kuiper et al. 1997). Genistein and daidzein are plant-derived 
estrogens which originate from soybean (Eldridge & Kwolek 1983). Genistein and daidzein 
have been shown to protect against menopausal symptoms, osteoporosis and hormone-
dependent cancers (for review, see Adlercreutz & Mazur 1997). 
 
In the premenopause, women have less cardiovascular diseases than men of the same 
age. After the menopause, the risk of these diseases increases. Postmenopausal estrogen 
replacement therapy (ERT) reduces this risk by 50% (Barret-Connor & Bush 1991). For 
many years the favourable effects of ERT on serum lipid values were considered to be the 
only factor in the decreased risk of cardiovascular diseases in postmenopausal women. 
ERT reduces serum total cholesterol, LDL (Nabulsi et al. 1993) and triglycerides (Bongard 
et al. 1998), and increases HDL (Nabulsi et al. 1993). Nowadays, it is estimated that only 
about 20-50% of the lowered risk is due to changes in lipid metabolism (Nasr & Breckwoldt 
1998). 
 
Hypertension is an important risk factor for cardiovascular diseases such as stroke and 
atherosclerosis. ERT reduces blood pressure in postmenopausal women (Luotola 1983; 
Szekacs et al. 2000). It also prevents the development of hypertension in various rat 
models such as the normotensive ovariectomized (OVX) Sprague-Dawley rat (Brosnihan 
et al. 1994), and normal (Iams & Wexler 1979; Williams et al. 1988) and OVX (Iams & 
Wexler 1979) female spontaneously hypertensive rats (SHR). SHR is an inbred strain, 
which develops hypertension with increasing age. SHR is a widely studied and probably 
the best animal model for human essential hypertension. 
 
The endothelium plays an essential role in regulating arterial tone and platelet 
aggregation, by secreting vasodilating substances such as nitric oxide (NO), prostacyclin 
(PGI2), and an endothelium-derived hyperpolarizing factor (EDHF) in response to 
physiological stimuli and mediators such as histamine and bradykinin. ERT protects the 
function of the endothelium. Although estradiol-17β relaxes arterial smooth muscle 
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endothelium-independently (Mügge et al. 1993), both oral ERT (Lieberman et al. 1994) 
and estradiol-17β infusion (Gilligan et al. 1994) improve endothelium-dependent 
vasodilation in healthy postmenopausal women. In female SHRs, estrogen treatment 
enhances endothelium-dependent relaxations of the aorta (Williams et al. 1988). ERT 
reduces the synthesis of endothelium-derived contracting factors (Dantas et al. 1999) and 
maintains NO synthesis in OVX SHRs (Huang et al. 1997). 
 
The tone of vascular smooth muscle cells (VSMCs) is controlled by the Ca2+ and K+ 
channels. When the Ca2+ channels open, the VSMC depolarizes and contracts. At the 
same time K+ channels open and K+ effluxes outside the cell. This causes 
hyperpolarization. It has been reported that the relaxing mechanism of estradiol-17β is 
related to the activation of K+ channels (White et al. 1995). 
 
Genistein inhibits tyrosine kinase by interacting with the ATP-binding site, whereas 
daidzein is inactive in this respect (Akiyama et al. 1987). The inhibitors of tyrosine kinases 
have been shown to reduce VSMC contractions (for review, see Hughes & Wijetunge 
1998). On the other hand, the substances which increase tyrosine phosphorylation in 
VSMC also induce contraction (Laniyonu et al. 1994). 
 
It is known that the plant-derived estrogens genistein and daidzein have beneficial effects 
on serum lipids (Anderson et al. 1995), but their effects on the cardiovascular system are 
still poorly understood. The aim of this study was to investigate the effects of genistein and 
daidzein on arterial tone and blood pressure in normotensive rats, and in male, female and 
OVX female SHRs, and to compare these effects with those of estradiol-17β. The following 
mechanisms of the action of plant-derived estrogens were studied: gender, endothelium, 
potassium channels, estrogen receptors, and the inhibition of tyrosine kinase. 
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2. REVIEW OF THE LITERATURE 
 
2.1. Plant-derived estrogens 
 
Plant-derived estrogens are substances which originate from plants and produce 
estrogenic effects, or are structurally or functionally similar to estradiol-17β (for review, see 
Fowler 1983). The estrogen-like activity of plant-derived estrogens was discovered 
because there were reports in Australia of reduced fertility in female sheep fed on fresh 
clover (Moule et al. 1963). Plant-derived estrogens are classified as lignans, isoflavones, 
and coumestans (Table 1).  
 
Table 1. Classification of plant-derived estrogens according to Korpela (1995). 
 
Class    Examples   Main sources 
Lignans   Enterolactone  Oilseed 
    Enterodiol   Linseed 
        Cereal bran 
        Whole cereals 
        Vegetables 
        Fruits 
        Legumes 
Isoflavones   Genistein   Soybean 
    Daidzein   Clover 
    Equol 
Coumestans   Coumestrol   Clover 
  
13
Plant-derived estrogens bind competitively to both estrogen α (ERα) and estrogen β (ERβ) 
receptors and activate them (Kuiper et al. 1997). ERα is called a classic ER and has been 
known for decades, while ERβ was described and characterized for the first time only a 
few years ago (Mosselman et al. 1996). Of all plant-derived estrogens, coumestrol has the 
most potent estrogen-like effect (Kuiper et al. 1997) (Table 2). It binds to ERα with a ten 
times lower affinity than estradiol17β, but its dissociation is close to that of estradiol-17β 
(Scarlata & Miksicek 1995). Coumestrol, however, is seldom found in the human diet. The 
methoxy derivative of genistein, biochanin A, does not bind ER, but is estrogenic in vivo 
(Miksicek 1994). Daidzein has a higher binding affinity to ER than its methoxy derivative, 
formononetin (Shutt & Cox 1972). It has been suggested that hydroxylation is necessary 
for a flavonoid to have estrogenic activity (Miksicek 1995). The flavonoids with hydroxyl 
substituents at 4’ and 7 positions are estrogenic, and an additional hydroxyl group at the 5 
position – like that possessed by genistein – increases estrogenic activity (Miksicek 1995). 
On the other hand, if a flavonoid has more than four hydroxyl substituents, (such as 
flavonol quercetin) or has a 4’-methoxylated substituent (such as hesperitin), the 
estrogenic activity is abolished (Miksicek 1995).  
 
Table 2. Relative binding affinity of various compounds to ERα and ERβ, according 
to Kuiper et al. (1997). 
 
Compound   ERα   ERβ 
Estradiol-17β   100   100 
Estrone   60   37 
Estriol    14   21 
Progesterone  <0.001  <0.001 
Testosterone   <0.01   <0.01 
Coumestrol   94   185 
Genistein   5   36 
β-Sitosterol   <0.001  <0.001 
Tamoxifen   7   6 
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2.1.1. Isoflavones 
 
Soy products are widely consumed throughout the world. In Asian countries, soy has been 
an important part of the diet for more than a thousand years. Soy is the main source of the 
isoflavones genistein and daidzein (Figure 1) (Eldridge & Kwolek 1983). The consumption 
of soy products is estimated to be highest among the Japanese population, with the levels 
of isoflavones reaching 200 mg/day (Cassidy et al. 1994). In other parts of Asia, the diet 
provides 25-40 mg of total isoflavones per day, whereas in the western countries less than 
5 mg/day is consumed (Coward et al. 1993). 
 
OHO
OH
OOH
  
OHO
OH
O
 
   
Genistein      Daidzein 
 
    
HO
OH
 
 
Estradiol-17β 
 
Figure 1. Structural formulas of, genistein, daidzein and estradiol-17β. 
 
Plant-derived estrogens, including isoflavones, are present in food as glycones, which are 
separated from other structural and storage components of the foods by the hydrolytic 
enzymes of gut bacteria (Setchell et al. 1982; Korpela 1995). In addition to the digestion of 
isoflavones from their glucose-containing precursors daidzin and genistin, daidzein may 
also be derived from formononetin and genistein from biochanin A. A significant portion of 
daidzein is further metabolized to equol, and genistein to p-ethylphenol (Figure 2). A major 
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proportion of plant-derived estrogens is excreted by the kidneys (for review, see Anderson 
& Garner 1997; Bingham et al. 1998). In humans, after a single soy meal the isoflavone 
concentrations rise slowly and reach maximum values of micromolar range at 7-8 hours 
(King & Bursill 1998). Genistein and daidzein have been detected in human plasma 
(Adlercreutz et al. 1994), urine (Adlercreutz et al. 1991), and milk (Franke & Custer 1996), 
as well as in saliva, breast aspirate and prostatic fluid (Finlay et al. 1991).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Intestinal metabolism of isoflavones, according to Anderson & Garner 
(1997). 
 
In rats daidzein conjugates are more bioavailable than genistein conjugates (King 1998). 
In plasma the maximum concentration of daidzein is approximately double that of genistein 
after a single oral dose of soy extract (King 1998). The pharmacokinetics of isoflavones 
are dependent on the form of administration. If isofavone, (like genistein alone or the 
equivalent dose of its glycone form, as an isoflavone-rich soy extract), is given to the rat, 
the plasma concentration rises faster in the genistein-treated rats than in the soy-extract-
treated rats (King et al. 1996). However, eight hours after administration, no differences 
exist in plasma concentration between the treatment groups (King et al. 1996), suggesting 
that the extent of absorption of genistein may be similar for both the glycone and the 
aglycone forms. 
 
Genistein and daidzein are available from a diet, and therefore their possible toxic effects 
have to be considered. Some animal studies of the toxicity of isoflavones exist. Normal 
Daidzin Daidzein Equol 
Formononetin 
Genistein Genistin p-Ethylphenol 
Biochanin A 
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dietary concentrations of genistein and daidzein, present in standard rat chow, are not 
toxic to rats and have only minimal effects on the reproductive tract (Casanova et al. 
1999). Neither a single dose of 40 mg/kg nor a cumulative dose of 100 mg/kg of genistein 
have been shown to exert toxicity in mice (Ek et al. 1998), and the intravenous 
administration of genistein over a period of five days is not toxic to monkeys (Messinger et 
al. 1998). 
 
β-Sitosterol is extracted from such plants as pine or soybean and has estrogenic effects. It 
increases uterine weight, RNA, DNA and protein concentrations to the same extent as 
estradiol and more than progesterone (Malini & Vanithakumari 1993). It also increases 
ovarian weight and has an estrogenic effect on the estrous cycle in rats (Malini & 
Vanithakumari 1988). On the other hand, β-sitosterol treatment decreases the ability of the 
testis to produce testosterone in goldfish (MacLatchy & Van Der Kraak 1995), and 
decreases testicular weight and testosterone concentrations in the blood of male rats 
(Malini & Vanithakumari 1991).  
 
2.1.2. Hormonal effects of isoflavones 
 
Plant-derived estrogens act as ER agonists or antagonists, depending on the hormonal 
status of the animal or man. Isoflavonoids at concentrations 100-1000 times higher than 
that of estradiol-17β have been considered to compete with endogenous mammalian 
estrogens, to bind ER, and to prevent estrogen-stimulated growth in mammals (for review, 
see Adlercreutz et al. 1995). It is therefore possible that the consumption of a diet rich in 
plant-derived estrogens could affect endogenic hormone production. The mid-cycle peaks 
of the luteinizing hormone and the follicle stimulating hormone are suppressed (Cassidy et 
al. 1995) or sometimes unaffected (Lu et al. 2000), and in premenopausal women the 
length of the follicular phase of the menstrual cycle is increased during an isoflavone-rich 
diet (Cassidy et al. 1995; Lu et al. 1996). The serum estradiol-17β concentration is 
unaffected (Cassidy et al. 1995; Honoré et al. 1997) or decreased (Lu et al. 1996; Lu et al. 
2000), the progesterone level is decreased (Lu et al. 1996; Lu et al. 2000), and the serum 
testosterone concentration is unaffected (Honoré et al. 1997), or reduced (Strauss et al. 
1998) by dietary isoflavone supplementation. 
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One of the most common symptoms of the menopause is hot flushes. The incidence of 
these is much lower in Malaysia (18%) and China (14%) than in western societies (70-
80%) (for review, see Knight & Eden 1995). The urinary levels of isoflavones in Japanese 
women are 100-1000 times higher than those in omnivorous women (Adlercreutz et al. 
1992). It has been suggested that this explains the low frequence of menopausal 
symptoms in the Japanese, although the effects of cultural backgrounds on these 
symptoms must be taken into account. When soybean flour is added to the diet, the 
incidence of hot flushes is reduced (Murkies et al. 1995). However, dietary wheat flour, 
which contains few plant-derived estrogens, also reduces hot flushes (Murkies et al. 1995). 
Thus, the precise effect of plant-derived estrogens on hot flushes is still unclear.  
 
Another important menopausal symptom is vaginitis, which is due to epithelial atrophy. 
When postmenopausal women consume a mixture of soy, linseed and clover, an increase 
in cell proliferation in the vaginal epithelium occurs (Wilcox et al. 1990), indicating 
estrogenic activity. However, opposite findings also exist. Soybean estrogens have no 
estrogenic effect on vaginal cytology in postmenopausal macaques (Cline et al. 1996) or 
women (Murkies et al. 1995). 
 
Osteoporosis is related to aging and especially to the menopause. After the cessation of 
ovarian function, women begin to lose their bone mass. The incidence of osteoporosis 
differs within populations, and according to the World Health Organaization report (1994) 
the incidence is lower in Asian women than in western women. One of the reasons for this 
could be the dietary differences between the areas, which are partly related to the 
consumption of soy products. Soy isoflavones have been shown to attenuate bone loss in 
perimenopausal women (Alekel et al. 2000) and in ovariectomized (OVX) rats (Arjmandi et 
al. 1998a). This may be due to enhanced bone formation rather than to slowed bone 
resorption (Arjmandi et al. 1998b). Although both genistein and daidzein are effective in 
preventing bone loss, daidzein is the more potent of these two compounds (Picherit et al. 
2000). 
 
To sum up, genistein and daidzein have estrogenic effects, which may be beneficial in 
treating menopausal symptoms. 
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2.1.3. Anticarcinogenic effects of isoflavones 
 
The incidence of breast, endometrial and ovarian cancer is lower in Asia and eastern 
Europe than in western countries (Rose et al. 1986). All these cancers are hormone-
dependent. Migrants from Asia who maintain their traditional diet have a decreased risk 
even when living in western countries (Kolonel 1988), whereas the increased risk of these 
diseases follows a change towards a westernized diet (Lee et al. 1991). An increased soy 
intake, for example, is associated with reduced breast cancer risk in both pre- and 
postmenopausal women (Wu et al. 1996) and with lowered prostate cancer risk in men 
(Jacobsen et al. 1998; Strom et al. 1999). For more references see review by Kurzer & Wu 
(1997). 
 
The anticarcinogenic effect of isoflavones has been studied widely in animal and in vitro 
models. A soy protein diet, for example, inhibits the growth of prostate adenocarcinoma in 
mice (Aronson et al. 1999; Bylund et al. 2000). In rats, three subcutaneous injections of 
genistein administered neonatally protect against mammary cancer (Lamartiniere et al. 
1995). On the other hand, in athymic mice, dietary genistein, which produces micromolar 
plasma concentrations, cannot inhibit the growth of estrogen-independent human breast 
cancer cells MDA-MB-231, but 10-80 times higher concentrations of genistein do inhibit 
the growth (Santell et al. 2000) and the DNA synthesis (Wang & Kurzer 1997) of these 
cells in cultures in vitro. 
 
Genistein, daidzein (Dixon-Shanies & Shaikh 1999), and biochanin A, a precursor of 
genistein (Dixon-Shanies & Shaikh 1999; Hsu et al. 2000), all inhibit the growth of the 
human ER positive breast cancer cells MCF-7. However, genistein (Twaddle et al. 1999), 
enterolactone and equol (Welshons et al. 1987), a derivative of daidzein, have also been 
shown to stimulate the growth of MCF-7 cells. The effect of many plant-derived estrogens 
on the DNA synthesis of MCF-7 cells is biphasic; at low concentrations (0.1-10 µM), 
genistein, biochanin A and enterolactone stimulate the DNA synthesis, whereas at high 
concentrations (20-80 µM) their effects are inhibitory (Wang & Kurzer 1997). This suggests 
that the low concentrations of plant-derived estrogens cause an estrogenic effect on MCF-
7 cells, but at high concentrations other mechanisms begin to have an influence. For more 
references see review by Tham et al. (1998). 
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Because genistein and various other plant-derived estrogens inhibit the growth of both 
estrogen-dependent and –independent mammary cancer cells, other mechanisms than 
estrogen antagonism must exist. These mechanisms possibly include tyrosine kinase 
inhibition (Twaddle et al. 1999), the arresting of the cells during the G2/M phase of the cell 
cycle (Fioravanti et al. 1998), the induction of apoptosis (Li et al. 1999), the inhibition of 
angiogenesis (Shao et al. 1998), and the inhibition of tumour cell invasion by the down-
regulation of matrix metalloproteinase synthesis (Shao et al. 1998). 
 
To sum up, plant-derived estrogens have anticarcinogenic effects on both hormone-
dependent and hormone–independent cancers in vitro, in animal models and also 
epidemiologically. 
 
2.1.4. Cardiovascular effects of isoflavones  
 
Epidemiologic studies have demonstrated a reduced rate of mortality due to coronary 
heart disease in Japanese populations consuming a traditional Japanese diet compared to 
a western diet (Kagan et al. 1974). Expatriate Japanese living in the United Kingdom have 
higher blood pressure and cholesterol levels and lower triglyceride levels than the 
Japanese still living in Japan (Robinson et al. 1995), which suggests that these differences 
are not of genetic origin but may be due to diet. The Japanese diet is rich in soy products, 
fish and fibre. 
 
2.1.4.1. Lipid metabolism 
 
In man, the consumption of soy protein has been shown to decrease the serum 
concentrations of total cholesterol, LDL cholesterol and triglycerides (Anderson et al. 
1995). The soy protein containing plant-derived estrogens have beneficial effects on 
serum lipid values, while the soy protein without plant-derived estrogens has no effect in 
mice (Kirk et al. 1998), in rhesus monkeys (Anthony et al. 1996), or in man (Crouse et al. 
1999). However, although plant-derived estrogens without soy protein do not affect serum 
lipid levels, but they reduce atherosclerotic lesion areas in the aortic arch and lower its 
cholesterol content at least in rabbits (Yamakoshi et al. 2000). The cholesterol-lowering 
and antiatherosclerotic mechanisms of soy may include reduced absorption of dietary 
cholesterol (Greaves et al. 2000), increased LDL receptor quantity and activity (Baum et 
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al. 1998; Kirk et al. 1998), the reduced arterial permeability of LDL, and the reduced 
arterial concentration and delivery of LDL (Wagner et al. 2000). (Table 3) 
 
Oxidized LDL is more prone than unoxidized LDL to remain in vessel wall and to induce 
atherosclerosis. In man, the intake of genistein and daidzein decreases LDL oxidation 
(Tikkanen et al. 1998). Isoflavones protect against glucose-induced oxidation of human 
LDL in vitro (Vedavanam et al. 1999). Both genistein and daidzein have also been shown 
to protect human umbilical cord endothelial cells and bovine aortic endothelial cells from 
the atherogenic effect of oxidized LDL (Kapiotis et al. 1997). Thus, the antioxidant property 
of the isoflavones may be important in decreasing the risk of atherosclerosis. 
 
Genistein is a more potent antioxidant than daidzein (Wei et al. 1995; Ruiz-Larrea et al. 
1997). The antioxidant properties of isoflavones are structure related (Wei et al. 1995; 
Ruiz-Larrea et al. 1997; Arora et al. 1998). The determining factors for isoflavonoid 
antioxidant activity are the absence of the 2, 3-double bond and the 4-oxo-group on the 
isoflavone nucleus and the position of the hydroxyl groups, with hydroxyl substitution being 
of utmost importance at the 4’ position, of moderate importance at the 5 position, and of 
little significance at the 7 position (Arora et al. 1998). 
 
To sum up, soy protein improves serum lipid values and inhibits the development of 
atherosclerosis. These favourable effects may be related to the plant-derived estrogens of 
soy. 
 
2.1.4.2. Other effects 
 
Although the effects of isoflavones on lipid metabolism are well understood, their other 
cardioprotective mechanisms have not been widely investigated. However, some studies 
do exist. For example, isoflavones influence the function of the endothelium. In the 
atherosclerotic macaque, dietary isoflavones enhance endothelium-dependent relaxation 
to acetylcholine (ACh) in the coronary arteries (Honoré et al. 1997), and treatment with 
genistein augments endothelium-dependent arterial relaxations in OVX rats (Squadrito et 
al. 2000). 
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VSMCs contribute to pathological structural changes within the vessel wall by migrating 
from the media into the intima, and by proliferating and depositing extracellular matrix 
proteins such as collagen (Dubey et al. 1997). Genistein, daidzein, biochanin A and equol 
inhibit human aortic VSMC proliferation, growth, migration and mitogen-activated protein 
kinase (MAP) activity (Dubey et al. 1999). The order of potency of these plant-derived 
estrogens is biochanin A > genistein > equol > daidzein (Dubey et al. 1999). In 
menopausal and perimenopausal women, dietary isoflavones improve arterial compliance 
(Nestel et al. 1997). Genistein has also been shown to reduce renal vascular resistance 
and to act as a diuretic (Gimenez et al. 1998), which can be beneficial in regulating blood 
pressure. (Table 3) 
 
In short, genistein and daidzein affect both the function of the endothelium and the smooth 
muscle of the vessel wall. 
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2.2. Postmenopausal estrogen replacement therapy (ERT) 
 
Estrogens are female sex hormones produced mainly by the ovaries. They regulate the 
growth and development of the female sex organs and other tissues related to 
reproduction. The most important of the estrogens is estradiol-17β. The secretion of 
estrogens ceases at the age of 45-55 years and the menopause begins. Estrogen 
replacement therapy (ERT) alleviates menopausal symptoms such as hot flushes and 
vaginitis. It protects women against many age- and hormone-related diseases such as the 
osteoporosis and cardiovascular diseases. Long-term use of ERT also improves excercise 
capacity in postmenopausal women (Redberg et al. 2000). 
 
2.2.1. Cardioprotective effects of ERT 
 
Premenopausal women have a lower risk of cardiovascular diseases compared to men of 
the same age. However, the incidence of coronary heart disease increases when estrogen 
levels decrease during the menopause. Epidemiological studies have shown an 
approximately 50% reduction in the risk of coronary incidents in postmenopausal women 
on ERT compared to non-users (Barret-Connor & Bush 1991). On the other hand, in those 
populations with low risk of cardiovascular diseases, the use of ERT for 10 years improves 
life expectancy by only about one month, doubled over 20 years (Moerman et al. 2000). 
However, women who have risk factors of cardiovascular diseases, such as high serum 
cholesterol and blood pressure, can benefit more from ERT (Moerman et al. 2000). 
 
2.2.1.1. Lipid metabolism 
 
For a long time, the beneficial effects of ERT on serum lipid values were considered to be 
the main reason for the decreased risk of cardiovascular diseases in postmenopausal 
women. During ERT, total cholesterol (Bongard et al. 1998; Chen et al. 1998), LDL 
(Nabulsi et al. 1993; Bongard et al. 1998; Chen et al. 1998; Herrington et al. 2000) and 
triglycerides (Bongard et al. 1998; Chen et al. 1998) are reduced, and HLD is increased 
(Nabulsi et al. 1993; Herrington et al. 2000). On the other hand, in postmenopausal 
women who use statins to lower cholesterol and to prevent atherosclerosis, ERT has no 
additional favourable effect on the lipid levels (Os et al. 2000). 
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Increased serum cholesterol and LDL predispose patients to both coronary and peripheral 
arterial atherosclerosis. Estrogen receptors are more expressed in normal coronary 
arteries than in atherosclerotic arteries in premenopausal women (Losordo et al. 1994), 
suggesting that the vascular endothelium and smooth muscle cells are targets of estrogen 
action. This agrees with the finding that ERT for one year or longer reduces the risk of 
peripheral arterial disease by about one half (Westendorp et al. 2000). However, in 
postmenopausal women with diagnosed coronary disease (Herrington et al. 2000) or with 
increased risk (Angerer et al. 2001), ERT combined with progesterone have no effect on 
the progress of atherosclerosis. 
 
Studies with experimental animals have also demonstrated the protective effect of ERT on 
atherosclerosis. In OVX rabbits, ERT prevents the development of the disease (Hanke et 
al. 1996), by preventing LDL accumulation in the arterial wall and by decreasing 
endothelial permeabilty to LDL (Walsh et al. 2000). This inhibitory effect of ERT on LDL 
accumulation may be due to the antioxidant property of estradiol-17β (Walsh et al. 1999). 
The beneficial influence of ERT may be dependent on the function of the endothelium. In 
OVX rabbits, ERT inhibits cholesterol accumulation if the endothelium is normal, has no 
effect in reendothelialized areas, and enhances cholesterol accumulation in 
deendothelialized areas (Holm et al. 1999). 
 
Thus, ERT has a beneficial influence on lipid metabolism, and this slows the development 
of atherosclerosis. However, it is still unclear whether the combining of progesterone with 
ERT destroys the protective effect of the ERT. 
 
2.2.1.2.  Vascular injury 
 
Both ERα and ERβ are expressed in VSMC (Register & Adams 1998). ERT inhibits VSMC 
proliferation and the increase of vascular media after injury in both ERα (Iafrati et al. 1997) 
and ERβ (Karas et al. 1999) deficient mice. This indicates that the protective effect of 
estradiol-17β requires only one type of functional ER at a time, or that some other still 
uncharacterized ER is involved. On the other hand, estradiol-17β has been shown to 
inhibit VSMC growth by stimulating cyclic adenosine 5’-monophosphate (cAMP) synthesis, 
leading to the formation of adenosine, which regulates growth via A2 adenosine receptors 
(Dubey et al. 2000). However, the concentration of estradiol-17β needed for activation of 
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cAMP synthesis is supraphysiological (Christ et al. 1999). After injury, the endothelium is 
also a target of ERT action, because ERT accelerates the recovery of the functional 
endothelium in OVX rats (Krasinski et al. 1997). 
 
2.2.1.3. Coagulation 
 
The use of oral contraceptives has been reported to increase the risk of venous 
tromboembolism. The risk is relatively high, especially in women using oral contraceptives 
with a high concentration of ethinylestradiol (for review, see Chasan-Taber & Stampfer 
1998). It has recently been shown that ERT plus progesterone also predispose women to 
tromboembolic events, at least in the case of women with established coronary disease 
(Grady et al. 2000). However, the situation may be totally different in healthy 
postmenopausal women, because in these subjects, this same medical combination 
decreases fibrinogen (Nabulsi et al. 1993), increases antitrombin III levels (Chen et al. 
1998), reduces platelet aggregation (Chen et al. 1998), and lowers plasma viscosity 
(Rosenson et al. 1998). 
 
2.3. Arterial tone 
 
Arterial tone is an important factor in the regulation of blood pressure. Arterial tone is 
determined by the interaction of the endothelium and the smooth muscle. 
 
2.3.1. Endothelium 
 
The vascular endothelium is a highly active endocrine organ covering the inner surface of 
the arteries and veins. In a person weighing 70 kg, the total surface area of the 
endothelium is about 1100 m2; it weighs approximately 1800 g, and the total number of 
cells is in the order of 1x1012. The endothelium is an important regulator of arterial tone 
because it secretes various vasodilating (Figure 3) and contracting substances. 
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2.3.1.1. Vasodilatory factors 
 
Nitric oxide 
In 1980 Furchgott and Zawadzki showed that the endothelium must be intact for ACh to 
induce arterial smooth muscle relaxation. A substance originating from a vessel with an 
intact endothelium caused relaxation in an arterial ring with a denuded endothelium; it was 
named “the endothelium-derived relaxing factor” (EDRF). Later the EDRF was confirmed 
to be nitric oxide (NO) (Ignarro et al. 1987; Palmer et al. 1987). NO is a gaseous free 
radical which is synthesized from the amino acid L-arginine by a family of NO syntethases 
(NOSs). NO relaxes VSMCs by increasing the production of cyclic guanosine 3',5'-
monophosphate (cGMP). 
 
A normal endothelium constantly releases small amounts of NO. Extra NO is released in 
response to physiological stimuli such as increased shear stress and reduced oxygen 
tension, and to substances such as ACh, bradykinin, histamine, thrombin, ADP, ATP, and 
the substance P. So far, NO is the most potent vasodilator known (for review, see Umans 
& Levi 1995). NO also inhibits platelet aggregation, neutrophil adhesion to the 
endothelium, VSMC proliferation, and adhesion molecule expression. The synthesis of NO 
is impaired in many diseases e.g. in hypertension, diabetes, hypercholesterolemia and 
atherosclerosis (for review, see Cannon 1998). In human endothelial cells, NO production 
is enhanced by estradiol-17β but not by testosterone (Hishikawa et al. 1995), and the 
physiological levels of circulating estradiol-17β elevate basal NO release from endothelial 
cells (Wellman et al. 1996). Pharmacologically, NO synthesis can be blocked by L-arginine 
analogs such as Nω-Nitro-L-arginine methyl ester (L-NAME). 
 
Prostacyclin 
Prostacyclin (PGI2 ) is formed from arachidonic acid (AA) by the cyclo-oxygenase enzyme. 
The endothelial cells are the highest producers of PGI2, but VMSCs and fibroblast are also 
able to synthetize PGI2. PGI2 is produced in response to shear stress and to substances 
that stimulate NO formation. The contribution of PGI2 to vasodilation is less than that of 
NO. However, PGI2 inhibits platelet aggregation and promotes fibrinolysis. Estrogens 
stimulate PGI2 synthesis in cultured human endothelial cells (Mikkola et al. 1996) and in 
the rat endothelium (Wakasugi et al. 1989), whereas testosterone reduces it (Wakasugi et 
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al. 1989). The synthesis of PGI2 is inhibited by common anti-inflammatory drugs such as 
acetylsalicylicacid, diclofenac, ibuprofen and tolfenamicacid. 
 
Endothelium-derived hyperpolarizing factor 
Endothelium-dependent relaxations and hyperpolarizations can be partially or totally 
resistant to the inhibitors of cyclo-oxygenase and NO synthetase, suggesting the existence 
of an additional endothelial relaxing mechanism. These NO- and PGI2-independent 
relaxations appear to be without an increase in the intracellular levels of cyclic nucleotides 
in smooth muscle cells, and the relaxations are antagonized by apamin and ChTX, the 
inhibitors of Ca2+ sensitive K+ channels (KCa) (for review, see Félétou & Vanhoutte, 1999). 
It has been suggested, therefore, that the hyperpolarization of smooth muscle cells caused 
by the opening of K+ channels is responsible for these relaxations, and the relaxing agent 
is called an endothelium-derived hyperpolarizing factor (EDHF). The nature of EDHF was 
for a long time unclear, but quite recently it has been discovered that EDHF may be an 
11,12-epoxyeicosatrienoic acid formed by cytochrome P450 2C from arachidonic acid, at 
least in the porcine coronary artery (Fisslthaler et al. 1999). 
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Figure 3. Simplified endothelium-dependent relaxing mechanisms of vascular 
smooth muscle. 
 
2.3.1.2. Vasocontracting factors 
 
Endothelin-1 
Three structurally and pharmacologically separate endothelin isopeptides exist in humans 
and mammals. These have been named endothelin-1 (ET-1), endothelin-2, and 
endothelin-3. Endothelial cells can synthesize only ET-1 (for review, see Masaki 1995). 
ET-1 is synthesized as a proendothelin, which is cleaved to the big endothelin and then, in 
a reaction, catalyzed by an endothelin-converting enzyme (ECE), and further converted to 
an active peptide. ET-1 exerts its biological effects by the stimulation of receptors called 
ETA and ETB. ETA and at lower amount ETB are present in VSMCs. Their stimulation 
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induces vasocontraction and mediates the proliferation of VSMCs. ETB receptors are also 
present in endothelial cells, where their stimulation is linked to the formation of PGI2 and 
NO. However, the most striking property of ET-1 is its long-lasting hypertensive action. It is 
the most active pressor substance discovered, with a potency 100 times that of 
angiotensin II (for review, see Masaki 1995). 
 
Angiotensin II 
When fluid volume or plasma Na+ concentration is reduced, the jugstaglomerular cells of 
the kidney are activated to secrete renin. Renin degrades angiotensinogen to angiotensin 
I, which is further cleaved to angiotensin II (Ang II) by an angiotensin-converting enzyme 
(ACE). Ang II contracts VSMC, induces the secretion of aldosterone from the adrenal 
cortex, and acts as a growth factor in VSMCs (for review, see Stroth & Unger 1999). It 
binds to its receptors AT1 and AT2. The vasoconstrictive and blood pressure increasing 
effects of Ang II are mainly mediated by AT1 receptors (for review, see Pueyo & Michel 
1997). Ang II also stimulates the release of ET-1 from endothelial cells. 
 
2.3.2. Smooth muscle 
 
2.3.2.1. Potassium channels 
 
Potassium channels (K+ channels) play an important role in determining smooth muscle 
excitability and force generation (Figure 4). In the cell membrane of the vascular smooth 
muscle, four different types of K+ channels have been identified: voltage-dependent (KV), 
Ca2+-activated (KCa), inward rectifier (KIR), and ATP-sensitive K+-channels (KATP) (for 
review, see Nelson & Quayle, 1995). 
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Figure 4. Potassium channels regulating the tone of vascular smooth muscle cells. 
 
 
Ca2+-activated K+ channels 
KCas are of diverse class of K+ channels that share the common feature of being gated by 
intracellular Ca2+. Many types of KCa have been described. They can be divided into three 
subclasses, based on differences in single-channel conductance, pharmacological 
properties, and the voltage dependence of channel openings. The high-conductance 
channels (maxi-channels) (100-300 pS) are usually blocked by ChTX and IbTX, and their 
gating is voltage-dependent. The intermediate-conductance channels (25-100 pS) are 
blocked by ChTX, and their gating is not voltage-dependent. Small-conductance channels 
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(10-20 pS) are typically inhibited by the bee venom toxin, apamin, and their open 
probability is unaffected by membrane potential. The maxi-channel is probably the most 
studied of the different types of KCa channels (for review, see Kaczorowski et al. 1996). 
 
The maxi-channels are opened by membrane depolarization and by micromolar 
concentrations of Ca2+. They are inhibited by tetraethylammonium (TEA) and a family of 
venom-derived peptides, such as ChTX and IbTX. TEA and ChTX also block other K+ 
channels, whereas IbTX is rather selective for maxi-channels. The maxi-channel consists 
of two dissimilar subunits, α and β. The α subunit is a member of the Ca2+-activated K+ 
channel gene family and forms the ion conduction pore. The β subunit is a structurally 
unique, membrane spanning protein that contributes to channel gating and pharmacology 
(for review, see Kaczorowski et al. 1996). The maxi-channels have been described in a 
wide range of smooth muscle cells (for review, see Nelson & Quayle 1995). Estradiol-17β-
induced relaxation is mediated via maxi-channels in coronaries (White et al. 1995). 
Estradiol-17β binds to the β subunit of this channel and the channel is opened (Valverde et 
al. 1999). 
 
Voltage-dependent K+ channels 
KV channels belong to the superfamily of voltage-gated channels. The KV channels open 
when the membrane potential of the cell is depolarized. They are important regulators of 
smooth muscle membrane potential. KV channels are identified in smooth muscle cells of 
coronary, mesenteric and renal arteries among others (for review, see Nelson & Quayle 
1995). 4-Aminopyridine (4-AP) at millimolar concentration is the most selective inhibitor 
known of KV channels in vascular smooth muscle. KV channels are unaffected by 
glibenclamide, IbTX and ChTX, but TEA inhibits them at high concentrations (for review, 
see Nelson & Quayle 1995). KV channels usually show inactivation with sustained 
depolarization (for review, see Standen & Quayle 1998). 
 
ATP-sensitive K+ channels 
ATP-sensitive K+ channels (KATP) are inhibited by physiological concentrations of 
intracellular ATP and are opened as intracellular ATP falls (for review, see Edwards & 
Weston, 1993). Under normal physiological conditions the channels are in a closed state 
(for review, see Edwards & Weston, 1990). KATP channels exist in different arterial smooth 
muscle cells (Standen et al. 1989). Whole cell KATP channel currents have been measured 
  
32
in single smooth muscle cells from pulmonary, coronary and mesenteric arteries (for 
review, see Nelson & Quayle 1995). KATP channels are inhibited by extracellular barium 
and by antidiabetic sulphonylurea drugs such as glibenclamide and glipizide (for review, 
see Nelson & Quayle 1995). The openers of this channel include minoxidil and cromakalim 
(for review, see Quast 1993). KATP channels have been shown to mediate testosterone-
induced relaxation in canine coronaries (Chou et al. 1996). 
 
Inward rectifier K+ channels 
Inward rectifier K+ channels (KIR) are present in a variety of excitable and nonexcitable 
cells including arterial smooth muscle cells. These channels may be preferentially 
expressed in small rather than large arteries (for review, see Standen & Quayle 1998). The 
KIR channels are activated by membrane hyperpolarization in contrast to the KV and KCa 
channels, which are activated by membrane depolarization. When the membrane potential 
is controlled, for instance by a voltage clamp of the cell, the movement of K+ from 
extracellular space to intracellular is larger than that from intracellular to extracellular. 
Extracellular barium in micromolar concentrations is an effective inhibitor of KIR channel 
(for review, see Nelson & Quayle 1995). 
 
To sum up, K+ channels seem to mediate estradiol-17β- and testosterone-induced 
relaxations of the arteries. 
 
2.3.2.2. Calcium channels 
 
In VSMCs two different types of voltage-gated calcium channels (Ca2+ channels) exist. 
Dihydropyridine-sensitive L-type voltage-gated Ca2+ channels appear to be dominant in 
most VSMCs, but T-type voltage-gated Ca2+ channels are also present (for review, see 
Hughes 1995). Voltage-gated Ca2+ channels play an important role in regulating vascular 
tone by membrane potential. Membrane depolarization opens these channels, which leads 
to vasocontraction, whereas hyperpolarization closes them, causing vasodilation. Ca2+ 
channel blockers are widely used in the treament of hypertension, arrythmias and angina 
pectoris.  
 
It has been suggested that estradiol-17β relaxes arteries by inhibiting L-type Ca2+ 
channels (Collins et al. 1993). In smooth muscle cell line (A7r5), estradiol-17β also inhibits 
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T-type Ca2+ currents (Zhang et al. 1994). In isolated smooth muscle cells, this inhibition of 
Ca2+ channels by estradiol-17β is non-genomic, and it reduces myosin light chain 
phosphorylation and contraction of the smooth muscle (Kitazawa et al. 1997). On the other 
hand, sex hormones also modify the density of Ca2+ channels. Long-term female sex 
hormone deficiency caused by ovariectomy has been reported as increasing and estrogen 
replacement as decreasing L-type Ca2+ channel expression in the rabbit myocardium 
(Patterson et al. 1998). Thus, estradiol-17β regulates both the function and the density of 
Ca2+ channels in muscle cells. 
 
2.3.2.3. Tyrosine phosphorylation 
 
Genistein is a tyrosine kinase inhibitor, while daidzein is inactive in this respect (Akiyama 
et al. 1987). Genistein inhibits tyrosine kinases via interaction with the ATP-binding site 
(Akiyama et al. 1987). Numerous tyrosine kinases have been described, and this 
superfamily of enzymes has been subdivided into receptor and non-receptor classes (for 
review, see Courtneidge 1994). Receptor tyrosine kinases are transmembranous proteins 
possessing intrinsic tyrosine kinase activity, which is regulated by an extracellular ligand, 
such as a growth factor, whereas non-receptor tyrosine kinases lack the extracellular 
recognition domain for ligands (for review, see Hughes & Wijetunge 1998). Tyrosine 
phosphorylation plays a role in such areas as growth, oncogenesis, and smooth muscle 
contraction. 
 
Tyrosine kinase activity is 500-800 times greater in smooth muscle than in skeletal or 
cardiac muscles (for review, see Di Salvo et al. 1997), indicating that tyrosine kinases are 
important regulators of the functions of VSMCs. Tyrosine kinase inhibitors have been 
shown to antagonize vascular contraction in response to a wide range of contractile agents 
in various arteries in vitro (for review, see Hughes & Wijetunge 1998). When [Ca2+] 
increases inside the smooth muscle cell, it contracts. The early transient increase of [Ca2+] 
is due to release from the stores and an influx of Ca2+, whereas the lower sustained 
component of this response is due to Ca2+ influx only. Because of its tyrosine kinase 
inhibiting capacity, genistein antagonizes both these components of Ca2+ increase 
reversibly (for review, see Di Salvo et al. 1997). Genistein also regulates the effect of Ca2+ 
on the contractile apparatus (Toma et al. 1995). 
 
  
34
To sum up, tyrosine kinases regulate the contraction of VSMCs, and the tyrosine kinase 
inhibitors such as genistein attenuate arterial contractions. 
 
2.4. Blood pressure 
 
High blood pressure is a common health problem in the industrialized countries. One-
quarter of the adult population in the USA suffers from hypertension (Burt et al. 1995), and 
in Finland over 10% of the population uses antihypertensive drugs (for review, see 
Nurminen et al. 1998). Hypertension is one of the main risk factors of cardiovascular 
diseases such as stroke and ischaemic heart diseases (Collins et al. 1990; MacMahon et 
al. 1990). Hypertension is also a predisposing factor for left ventricular hypertrophy (LVH), 
which increases the risk of myocardial infarction, sudden death, cardiac arrhythmias and 
congestive hearth failure (Frohlich et al. 1992). Both clinical and experimental studies have 
shown that hypertension also has a detrimental effect on the kidneys (Whelton & Klang, 
1989). 
 
2.4.1. Protective effects of estrogens on blood pressure and its complications 
 
The higher incidence of hypertension in men and postmenopausal women than in 
premenopausal women (Kannel et al. 1976; for review, see Farhat et al. 1996) suggests 
that female sex hormones in premenopausal women have beneficial vascular effects. The 
beneficial effects of ERT in postmenopausal women further support a protective role for 
estrogens against hypertension (Stampfer et al. 1991). ERT lowers blood pressure in 
postmenopausal women (Luotola 1983; Szekacs et al. 2000) or leaves it unaffected 
(Nabulsi et al. 1993; Chen et al. 1998). Although ERT in some patients lowers blood 
pressure, it protects neither young (Pedersen et al. 1997) nor old (Fung et al. 1999) 
postmenopausal women from stroke. However, LVH is reduced (Lim et al. 1999) and left 
ventricular function is improved (Chen et al. 1998) by ERT. 
 
The attenuating effect of estrogen on the development of hypertension has been 
demonstrated in animal studies. In the normotensive OVX Sprague-Dawley rat (Brosnihan 
et al. 1994), in normal (Hoeg et al. 1977; Iams & Wexler 1979; Williams et al. 1988) and 
OVX (Iams & Wexler 1979) female SHRs, in OVX spontaneously hypertensive heart 
failure rats (Sharkey et al. 1999), in OVX trasgenic (mRen2)-27 positive and negative rats 
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(Brosnihan et al. 1997), and in OVX rats with deoxycorticosterone-induced hypertension 
(Crofton & Share 1997), estrogen treatment attenuates the development of hypertension. 
On the other hand, in Dahl`s salt-sensitive rats OVX increases the development of 
hypertension (Hinojosa-Laborde et al. 2000). However, when ERT is given to an old 
postmenopausal spontaneously hypertensive heart failure rat, it has no decreasing effect 
on already developed hypertension (Sharkey et al. 1999). Thus, ERT attenuates the 
development of hypertension in many rat models, but the beneficial effect disappears if 
treatment begins after hypertension has already developed. 
 
One important mechanism in lowering blood pressure may be estrogen-induced 
vasodilation. Estrogen has been shown to relax different arteries in many species - e.g. 
human (Mügge et al. 1993), rabbit (Jiang et al. 1991), porcine (Teoh et al. 2000) and rat 
(Otter & Austin 1998) coronary arteries, and rat mesenteric arteries (Naderali et al. 1999). 
 
As well as relaxing arterial smooth muscle, estradiol-17β can enhance the relaxations 
caused by other substances or by physiological stimuli. Both oral ERT (Lieberman et al. 
1994) and an estradiol-17β infusion (Gilligan et al. 1994) improve endothelium-dependent 
vasodilation in healthy postmenopausal women. ERT combined with progesterone fails to 
protect women against age-related decline in endothelium-dependent vasodilation 
(Sorensen et al. 1998), suggesting that progesterone may attenuate the beneficial effects 
of estrogen. However, ERT (Lieberman et al. 1994), estradiol-17β infusion (Gilligan et al. 
1994), and ERT plus progesterone (Sorensen et al. 1998) have no effect on endothelium-
independent vasodilation in postmenopausal women. 
 
In female SHRs, estrogen treatment enhances the endothelium-dependent relaxations of 
the aorta (Williams et al. 1988). In OVX SHRs, ERT reduces the synthesis of endothelium-
derived contracting factors such as PGH2/PGF2α (Dantas et al. 1999) and maintains the 
NO synthesis (Huang et al. 1997). Physiological estradiol-17β levels elevate basal NO 
release from rat coronary endothelial cells (Wellman et al. 1996) and arterial segments 
(Krasinski et al. 1997). 
 
In short, ERT lowers blood pressure in man and attenuates the development of 
hypertension in animal models. This may be due to the decreased peripheral resistance 
caused by direct arterial relaxation with estradiol-17β, or by the increased production of 
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vasodilating substances in the endothelium and the reduced production of vasocontracting 
ones. 
 
2.4.2. Effect of soy on blood pressure 
 
Some studies on the effect of soy protein and its isoflavones on blood pressure exist. In a 
clinical trial with normotensive volunteers, the replacement of meat by soy protein did not 
alter blood pressure (Bursztyn & Van Dias 1985). However, soy protein supplementation, 
which contains isoflavones, lowers diastolic blood pressure in perimenopausal women 
(Washburn et al. 1999). On the other hand, isoflavones without soy protein have no effect 
on blood pressure in subjects with high to normal blood pressure levels (Hodgson et al. 
1999). It is still poorly understood whether soy protein and isoflavones affect the 
development of hypertension. 
  
37
3. AIMS OF THE STUDY 
 
Estrogens protect women against cardiovascular diseases by improving serum lipids, by 
lowering blood pressure and by dilating arteries. Genistein and daidzein are among the 
most common plant-derived estrogens, which have been shown to lower serum total and 
LDL cholesterols and to increase serum HDL cholesterol. The mechanisms of action of 
genistein and daidzein on the cardiovascular system have not been widely investigated. 
 
The aims of the present study were: 
 
1. To compare the effects of estradiol-17β, genistein and daidzein on arterial tone in vitro 
(Study I). 
 
2. To clarify the role of potassium channels in estradiol-17β-, genistein- and daidzein-
induced arterial relaxation (Study II). 
 
3. To examine the effect of gender and ovariectomy on arterial contractions and 
relaxations (Study III). 
 
4. To investigate the effect of a soy-based diet on the development of hypertension in 
male and female spontaneously hypertensive rats (SHR) (Study IV). 
 
5. To evaluate the actions of estradiol-17β and genistein as estrogen receptor agonists 
and tyrosine kinase inhibitors (Study V). 
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4. MATERIALS AND METHODS 
 
4.1. Experimental animals 
 
Male and non-pregnant female Wistar rats (250-350 g) were purchased from Animal 
House Arkadia, University of Helsinki. Male, non-pregnant female and OVX female SHRs 
were purchased form Harlan Sprague Dawley Inc, Indiana, IN, USA. The rats were housed 
five animals to a cage in a standard experimental animal laboratory, and had free access 
to tap water. All the rats in Studies I, II, III, and V were provided with standard laboratory 
food pellets (R36, Lactamin, Special foderföretaget, Stockholm, Sweden). In Study IV, the 
control group received a standard rat chow (R36, Lactamin, Stockholm, Sweden). One 
group received a diet produced by adding 20 g of 85.5% casein, (Valio Ltd, Helsinki, 
Finland) to 80 g of the standard rat chow, and another group received a diet produced by 
adding 20 g of 90% soy protein (SUPRO 670, Protein Technologies International, St. 
Louis, Mo, USA) to 80 g of the standard rat chow. All these diets had a final NaCl content 
of 0.54% and the supplementation period was five weeks. In Study V, the following 
treatments were given subcutaneously once a day for either two days or for two weeks 
each to the different rat group, as follows: control 96% DMSO 1ml/kg, estradiol-17β 25 
µg/kg, genistein 2.5 mg/kg, or genistein 25 mg/kg. 
 
4.2. Arterial responses 
 
4.2.1. Arterial preparations and organ bath solution 
 
The superior mesenteric and renal arteries were carefully excised and cleaned of adherent 
connective tissue for functional in vitro studies (Pörsti et al. 1991). One to six 3-mm-long 
sections of the mesenteric, and one or two 2-mm-long sections of the renal arteries were 
prepared and placed between stainless steel hooks and mounted in an organ bath 
chamber in Krebs-Ringer buffer (pH 7.4) of the following composition (mM): NaCl (119.0), 
NaHCO3 (25.0), glucose (11.1), CaCl2x2H2O (1.6), KCl (4.7), KH2PO4 (1.2), MgSO4x7H2O 
(1.2), which was then aerated with 96% O2 and 4% CO2. 
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4.2.2. Arterial relaxation and contraction responses 
 
The rings were equilibrated for 1 h at +37°C with a resting tension of 1.0 g for the 
mesenteric and 0.2 g for the renal arteries. The force of contraction was measured with an 
isometric force-displacement transducer and registered with a polygraph (FT03 
transducer, Model 7P122E Polygraph; Grass Instrument Co., Quincy, MA, USA.). 
Acetylcholine (ACh)-induced (1 µM) relaxation after noradrenaline (1 µM) precontraction 
was used to test the presence or the absence of endothelium. 
 
Estradiol-17β-, genistein- and daidzein-induced relaxations 
In Study I, cumulative relaxations to estradiol-17β, genistein and daidzein were determined 
after noradrenaline-, potassium chloride- and calcium chloride-induced precontraction in 
both endothelium-intact and endothelium-denuded mesenteric arterial rings. Each 
concentration of the relaxing drug was allowed to take its effect for 10 min before the next 
concentration was administered. Some of the endothelium-intact arterial rings were 
pretreated with diclofenac or L-NAME or both, in order to study the role of PGI2 and NO on 
the relaxations. Pretreatment lasted 15 min. In Study II, a single concentration of each 
compound was administered after noradrenaline precontraction and was allowed to take 
its effect for 30 min. 15 min before the contraction, the rings were pretreated with different 
K+ channel antagonists such as ChTX, IbTX, apamin, 4-AP, barium or glibenglamide, or 
with an estrogen receptor antagonist, tamoxifen. 
 
Other relaxation responses 
The cumulative concentration response curves were studied for ACh and sodium 
nitroprusside (SNP) (III, IV, V) as described by Kähönen et al. (1993). In Study V, part of 
the rings were pretreated with diclofenac, L-NAME, TEA or a combination of all these 
drugs in order to clarify the role of PGI2, NO and KCa channels on the ACh-induced 
relaxations. 
 
Contraction responses 
The cumulative concentration-response curves were determined for noradrenaline and 
potassium chloride (III, IV, and V), for calcium chloride in hyperpolarized media (IV), and 
for ET-1 (V). Only a single dose each of Ang I and Ang II was administered in order to 
avoid tachyphylaxis (V). 
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4.3. Measurement of systolic blood pressure and heart rate 
 
The systolic blood pressure and the heart rate of the pretrained rats were measured at the 
beginning and at the end of the study (IV, V) using a tail-cuff analyzer (Apollo-2AB Blood 
Pressure Analyzer, Model 179-2AB, IITC Life Science, Woodland Hills, CA, USA). Before 
the measurements the rats were warmed for 10-20 min at 30°C to make the pulsations of 
the tail artery detectable. The values for systolic blood pressure and heart rate were 
obtained by averaging readings from three consecutive measurements. To minimize 
stress-induced variations in blood pressure, all measurements were taken by the same 
person in the same peaceful environment. 
 
4.4. Collection of samples 
 
The rats were kept for 24 h in their metabolic cages. They had free access to chow and 
tap water. Food and water consumption was determined, and the urine was collected (V). 
 
The rats were rendered unconscious with CO2/O2 70/30% (AGA, Riihimäki, Finland) and 
then decapitated. Blood samples were taken and placed in chilled tubes and centrifuged at 
+4°C (IV, V). The heart was excised, the large blood vessels, the atria and the free wall of 
the right ventricle were dissected, and the left ventricular was weighed (IV, V). The 
kidneys, uteri (IV, V), testicles and ovaries (IV) were excised, washed with ice-cold saline 
and weighed. Organ-weight-to-body-weight ratios were calculated to describe the 
hypertrophy or atrophy of these organs. 
 
4.5. Histology 
 
Tissue samples from the superior mesenteric artery, the right renal artery and the uterine 
horns were prepared and fixed for 24-48 h with 10% formaldehyde. The samples were 
dehydrated and embedded in paraffin using the standard protocol. Cross-sections (5 µm 
thick) of the arteries and uteri were deparaffinized, hydrated, and stained with Masson’s 
trichrome, or with hematoxylin and eosin. The slides were examined in a blinded fashion 
(V). 
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4.6. Biochemical determinations 
 
4.6.1. Serum cholesterol, LDL, HDL and triglyceride concentrations 
 
Serum cholesterol and triglyceride concentrations were measured with enzymatic 
colorimetric tests (Boehringer Mannheim GmbH, Mannheim, Germany), and serum HDL 
concentrations with a homogeneous enzymatic colorimetric test (Boehringer Mannheim 
GmbH, Mannheim, Germany). Serum LDL concentrations were estimated with the 
Friedewald formula. 
 
4.6.2. Serum estradiol-17β and testosterone concentrations 
 
Serum estradiol-17β concentrations were measured with a competetive 
radioimmunoassay (RIA) (Orion Diagnostica, Turku, Finland). Before RIA, the samples 
were extracted with diethylether, the organic phase was evaporated and the dried residue 
was dissolved with estradiol zero serum. Serum testosterone concentrations were 
measured with an automated direct competitive chemiluminoimmunoassay (CIA) (Chiron 
Diagnostics Corporation, Emeryville, CA, USA). 
 
4.6.3. Urinary creatinine and electrolyte excretions 
 
Urine creatinine was analyzed by the Jaffe method (Bartels et al. 1972) (BM/Hitachi 917 
analyzer, Boehringer Mannheim, Germany/Hitachi Ltd, Tokyo, Japan) without 
deproteinization. Urine sodium and potassium were determined by a flame photometer 
using an ion-selective electrode compensator (human serum pool, IL model 943, 
Instrumentarium Laboratory, Milan, Italy). Urine calcium was determined by the method 
described by Cali et al. (1973). 
 
4.6.4. Aortic nitric oxide synthase expression 
 
Aorta tissues were homogenized, using an Ultra-Turrax homogenizer, in five volumes of 
boiling lysis buffer (1% sodium docecyl sulfate (SDS), 1.0 mM Na3VO4, 10 mM Tris pH 7.4) 
(Sigma, St. Louis, MO, USA). The protein content of the supernatants was measured 
according to the method of Lowry et al. (1951). Equal amounts of protein (30 µg) were 
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resolved by 8% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to the 
nitrocellulose membranes (Hybond-C Extra, Amersham, Buckinghamshire, UK) (Laemli 
1970). The membranes were incubated with the mouse monoclonal anti-eNOS IgG1 
(1:2500,Transduction Laboratories, Lexington, KY, USA), followed by incubation with the 
horseradish peroxidase-coupled anti-mouse IgG1 (1:1000, Zymed Laboratories, San 
Francisco, CA, USA). The bound antibodies were detected using an ECL (enhanced 
chemiluminescence) reagent (Amersham). Homogenized rat aortas and prestained 
molecular marker proteins (Bio-Rad Laboratories, Hercules, CA, USA) were used as a 
positive control. Each band was quantified with computer programmes (GeneSnap and 
GeneTools, Synoptics, Cambridge, UK). 
 
4.6.5. Vascular smooth muscle tyrosine phosphorylation 
 
To study tyrosine phosphorylation, the mesenteric arterial (II) or aortic (V) rings were 
homogenized, using an Ultra-Turrax homogenizer, in five volumes of boiling lysis buffer 
(10 mM Tris, pH 7.4, 1% sodium docecyl sulfate (SDS), 1.0 mM Na3VO4, 50 mM NaF). 
The protein content of the supernatants was measured according to the method of Lowry 
et al. (1951). The supernatants were boiled in reducing Laemmli sample buffer, and 10 µg 
samples were separated in 4-15% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Immunodetection was performed using an anti-
phosphotyrosine antibody (clone 4G10, Upstate Biotechnology, New York, NY, USA), 
biotinylated anti-mouse immunoglobulins (Dako A/S, Glostrup, Denmark) and streptavidin-
biotin horseradish-peroxidase-conjugated secondary antibodies (ECL, Amersham 
Pharmacia Biotech, Buckinghamshire, UK), followed by detection by enhanced 
chemiluminescence (ECL, Amersham Pharmacia Biotech). 
 
4.7. Cell cultures 
 
Rat aortic smooth muscle cells were isolated by an explant method (Ross 1971) from the 
thoracic aortas of male Wistar rats. The smooth muscle cells were cultured in Dulbecco`s 
Modified Eagle`s Medium/Nutrient Mixture F-12 (DMEM/F12, 1:1) supplemented with 10% 
fetal bovine serum, HEPES (15 mM), and antibiotics. The cells (passages 4-6) were 
pretreated with genistein (10-100µM), daidzein (10-100µM) or a control vehicle, for 15-30 
min before the addition of orthovanadate (10-100µM). After 10-15 min of incubation with 
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orthovanadate, the cells were lysed with a Triton lysis buffer (50 mM TRIS pH 7.4,10% 
glycerol, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 50 mM NaF, 1mM Na3VO4, and 
protease inihibitors). The protein concentrations of the supernatants were determined 
using the Bio-Rad protein assay system (Bio-Rad Laboratories). SDS-PAGE and 
immunodetection were performed as described above. 
 
4.8. Compounds 
 
The following compounds were used: acetylcholine chloride, angiotensin I acetate, 
angiotensin II acetate, 4-aminopyridine, apamin, charybdotoxin, daidzein (purity 98%), 
diclofenac, endothelin-1, estradiol-17β (purity 98%), genistein (purity 98%), iberiotoxin, 
Nω-Nitro-L-arginine methyl ester, noradrenaline bitartrate, sodium orthovanadate, 
tetraethylammonium acetate (Sigma Chemical Co, St. Louis, MO, USA), barium chloride 
(E. Merck AG, Darmstad, Germany), β-sitosterol (Kaukas Ltd, Chemical Mill, 
Lappeenranta, Finland), glibenclamide (Leiras Ltd, Turku, Finland), sodium nitroprusside 
(F. Hoffmann La Roche Ltd, Basel, Switzerland) and tamoxifen citrate (Calbiochem-
Novabiochem Corporation, La Jolla, CA, USA). The estradiol-17β (I, II) genistein (I, II), 
daidzein (I, II), β-sitosterol and tamoxifen were dissolved in ethanol. The 4-Aminopyridine, 
barium chloride, estradiol-17β (V), genistein (V), glibenclamide and tetraethylammonium 
were dissolved in DMSO (96%). The other compounds were dissolved in water. The 
solutions were prepared just before use and protected from light. 
 
4.9. Statistical analysis 
 
The results are expressed as means ± S.E.M. The sensitivity of the artery to the 
cumulative relaxation response is presented as pD2 values, which are calculated as the 
negative log of the dose required to produce the half-maximal response (I, IV, V). The 
results of cumulative concentration response curves were analyzed using two-way 
analysis of variance (MANOVA) with repeated measurements. Duncan`s test (III, IV) and 
Newman-Keuls` test (I, V) were used for pairwise comparisons between the treatment 
groups. Other data were analyzed with one-way analysis of variance. Newman-Keuls` test 
(II) and a Student`s t-test (V) were used for the comparison of the means. P< 0.05 was 
considered significant. 
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4.10. Ethics 
 
The studies were approved by by the Animal Experimentation Committee of the Institute of 
Biomedicine, University of Helsinki. 
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5. RESULTS 
 
5.1. Arterial tone 
 
5.1.1. Effects of estradiol-17β, genistein, daidzein and β-sitosterol on arterial tone in 
vitro 
 
In endothelium-intact female mesenteric arterial rings precontracted with either 
noradrenaline (1 µM), potassium chloride (60 mM), or calcium chloride (1 mM), estradiol-
17β (1-100 µM), genistein (1-100 µM) and daidzein (1-100 µM) induced a cumulative 
dose-dependent relaxation response compared to an ethanol control in female rats. These 
relaxation responses were also tested with male mesenteric arterial rings, and no 
statistical difference was found compared to the rings from female rats. β-Sitosterol (1-100 
µM) only relaxed noradrenaline precontracted endothelium-intact rings, but the relaxation 
was not statistically significant. In potassium chloride and calcium chloride precontracted 
rings, estradiol-17β was the most potent relaxant, and genistein was more potent than 
daidzein. Pretreatments with diclofenac, an inhibitor of PGI2-production, or L-NAME, an 
inhibitor of NO-synthesis, did not alter these relaxations. No differences existed between 
the endothelium-intact and –denuded rings (I). 
 
Estradiol-17β-induced (10 µM) relaxation was inhibited by IbTX (30%) but not by ChTX, 
both of which are inhibitors of large conductance KCa-channels. Apamin, an inhibitor of 
small conductance KCa-channels, attenuated estradiol-17β-induced relaxation by 45%. 
Genistein-induced (10 µM) relaxation was also significantly inhibited by IbTX (50%) and 
ChTX (60%), but not by apamin. The relaxation response of daidzein (10 µM) was reduced 
by IbTX (50%), ChTX (60%) and apamin (50%) (II). 
 
4-AP, an inhibitor of KV-channels, had no effect on estradiol-17β-, genistein- or daidzein-
induced relaxation responses. Nor did glibenclamide, an inhibitor of KATP-channels, 
barium, an inhibitor of KIR-channels, or TEA, an unspecific inhibitor of KCa-channels, alter 
the relaxation responses (II). 
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To sum up, the relaxations induced by estradiol-17β, genistein and daidzein were 
endothelium- and gender-independent, and the relaxations were mediated, at least partly, 
via KCa-channels. 
 
5.1.2. Effects of gender, ovariectomy, low- and high-dose genistein, and estradiol-
17β treatments on arterial tone 
 
Mesenteric artery 
In normotensive Wistar rats, male gender augmented the mesenteric arterial contractions 
to noradrenaline (10 nM-10 µM) by approximately 50% and to potassium chloride (20-125 
mM) by 30% compared to female rats with intact ovaries. The OVX Wistar female rats had 
25% higher noradrenaline-induced and 20% higher potassium chloride-induced 
contractions than normal female rats (III). In both male and female SHRs, the soy protein 
diet had no effect on noradrenaline- (1 nM-100 µM), potassium chloride- or calcium 
chloride-induced (10 µM-10 mM) contractions (IV). 
 
The endothelium-dependent relaxations to ACh (1 nM-10 µM) were unaffected by gender 
and OVX, whereas the endothelium–independent relaxations to SNP (1 nM-10 µM) were 
enhanced in normal female Wistar rats compared to the males (III). OVX shifted the dose-
response curve to SNP to the right, in the direction of that of the males (III). In the male 
and female SHRs, the soy protein diet had no effect on ACh- or SNP-induced relaxations 
(IV). In OVX SHRs, neither the two-day low-dose (2.5 mg/kg/d) nor the high-dose genistein 
(25 mg/kg/d), nor the estradiol-17β (25 µg/kg/d) treatments influenced the ACh- or SNP-
induced maximum relaxations ex vivo. When diclofenac, L-NAME and TEA were added in 
vitro as pretreatments, the maximum ACh relaxations did not differ between the genistein 
and estradiol-17β groups. After the two-week genistein or estradiol-17β treatments, ACh- 
and SNP-induced relaxations were similar to those seen after the two-day treatments (V). 
 
To sum up, male gender and OVX in Wistar rats increased noradrenaline- and potassium 
chloride-induced contractions. Male gender and OVX decreased the SNP-induced 
relaxations, while neither the soy protein supplementation, nor the low- or high-dose 
genistein, nor the estradiol-17β treatments had any effect on endothelium-dependent or -
independent relaxations in the mesenteric artery (Table 4). 
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Renal artery 
Renal artery contractions were attenuated by the two days of low-dose genistein treatment 
as follows: Ang II (1 µM) (46%), noradrenaline (42%), potassium chloride (36%), and ET-1 
(0.1 nM-33 nM) (34%). Only the Ang II-induced contractions were reduced by the two-
week treatment with estradiol-17β (38%) and with the low-dose of genistein (31%) 
compared to the controls. No differences existed in Ang I-induced (1 µM) contractions 
between the treatment groups after the two-day or two-week interventions (V). 
 
The relaxations induced by ACh (1nM-1 µM) and SNP (0.1 nM-1 µM) were unaffected by 
the genistein or estradiol-17β treatments. SNP-induced dose-response curves shifted to 
the left in all the groups after the two-week treatments compared to the two-day 
treatments. At the end of two weeks the controls were the most sensitive to SNP relaxation 
(V). 
 
In short, the two-day low-dose genistein treatment of the OVX SHRs attenuated renal 
arterial contractions ex vivo, whereas the endothelium-dependent and -independent 
relaxations remained unaffected (Table 4). 
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Table 4. Summary of effects of male gender, OVX, soy protein diet, and genistein 
and estradiol-17β treatments on arterial function in rats. NA noradrenaline; KCl 
potassium chloride; ACh acetylcholine; SNP sodium nitroprusside; ET-1 endothelin-
1; Ang II angiotensin II. 
 
Mesenteric arteries  NA KCl ACh SNP 
Normotensive rats 
Male gender   ↑ ↑ ↔ ↓ 
OVX    ↑ ↑ ↔ ↓ 
SHRs 
 Soy protein diet  ↔ ↔ ↔ ↔ 
OVX SHRs 
 Low-dose genistein    ↔ ↔ 
 High-dose genistein    ↔ ↔ 
 Estradiol-17β     ↔ ↔ 
 
Renal arteries   NA KCl ACh SNP ET-1 Ang II 
Two-day treatment 
Low-dose genistein  ↓ ↓ ↔ ↔ ↓ ↓ 
High-dose genistein  ↔ ↔ ↔ ↔ ↔ ↔ 
Estradiol-17β   ↔ ↔ ↔ ↔ ↔ ↔ 
Two-week treatment 
Low-dose genistein  ↔ ↔ ↔ ↔ ↔ ↓ 
High-dose genistein  ↔ ↔ ↔ ↔ ↔ ↔ 
Estradiol-17β   ↔ ↔ ↔ ↔ ↔ ↓ 
↑ increased 
↓ decreased 
↔ no effect 
  
49
5.2. Blood pressure 
 
Systolic blood pressure was 15 mmHg lower in female and 19 mmHg lower in male SHRs 
on a soy protein diet compared to female and male SHRs on a casein diet. There were no 
differences in blood pressure values between the female and the male SHRs (IV). The 
two-week treatments with estradiol-17β (25 µg/kg/d), low-dose genistein (2.5 mg/kg/d) or 
high-dose genistein (25 mg/kg/d) did not significantly alter blood pressure compared to the 
OVX SHR controls (V). 
 
5.3. Body and organ weights 
 
The casein or soy protein supplementation did not alter the body weights in any of the 
different diet groups in the SHRs. The male rats weighed about 50% more than the 
respective females (IV). In OVX SHRs, the two-week treatment with estradiol-17β and 
high-dose genistein lowered body weights compared to the controls (V). 
 
Both soy and casein supplementation in the diet induced a significant renal hypertrophy in 
both female and male SHRs compared to the SHRs on the control diet. Neither the soy nor 
the casein supplementation altered uterial, ovarial or testical weights (IV). In the OVX 
SHRs, the two-day treatment with estradiol-17β and high-dose genistein induced 
hypertrophy in the uteri (V), as did the two-week treatment with both low- and high-dose 
genistein and with estradiol-17β. 
 
5.4. Tissue morphology 
 
Both the two-day and the two-week estradiol-17β treatments, as well as the two-week 
high-dose genistein treatment, all caused estrogenic changes in uterine morphology (V). 
 
Neither the two-day nor the two-week treatment with estradiol-17β, nor the low- or high-
dose genistein altered the morphology of the renal and mesenteric arteries in the OVX 
SHRs. Every sample had normal intimal, medial and adventitial morphology (V). 
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5.5. Biochemical determinations 
 
5.5.1. Serum cholesterol, LDL, HDL, and triglyceride concentrations 
 
The five-week soy protein supplementation reduced serum total cholesterol levels in both 
the female rats (20%) and the male rats (10%), and HDL-levels in the female rats (20%). 
Serum total cholesterol, HDL and triglycerides were all 30-45% higher in the female rats 
compared to the males. The different diets did not affect triglyceride levels. Serum LDL-
concentrations were below the detection limit in all the groups (IV). 
 
5.5.2. Serum estradiol-17β and testosterone concentrations 
 
The soy protein supplementation reduced serum estradiol-17β concentration by 60% 
compared to the control diet. The serum testosterone concentrations were unaffected by 
the soy or the casein diets in SHRs (IV). 
 
5.5.3. Urinary creatinine and electrolyte excretions 
 
The daily urine sodium and calcium excretions decreased, (17% and 40% respectively), in 
the high-dose genistein animals compared to the control rats, while no differences 
appeared between the groups in the daily urine potassium excretion. Creatinine excretion 
was also similar in all the OVX SHR groups (V). 
 
5.5.4. Aortic nitric oxide synthase expression 
 
Neither the two-day nor the two-week treatments with estradiol-17β, low- or high-dose 
genistein affected the amount of eNOS protein measured by western blotting in the aortic 
tissue of the OVX SHRs (V). 
 
5.5.5. Vascular smooth muscle tyrosine phosphorylation 
 
Orthovanadate (100 µM) increased tyrosine phosphorylation in the mesenteric arterial 
rings. Genistein pretreatment for 15 min at a concentration of 10 µM slightly reduced 
phosphorylation, and at a 10 times higher concentration decreased it clearly. Both daidzein 
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10 µM and 100 µM pretreatments reduced phosphorylation slightly, but less than genistein 
100 µM (II). 
 
In the VSMC culture, orthovanadate increased tyrosine phosphorylation. Neither a low 
concentration of genistein (10 µM) nor a daidzein pretreatment modified phosphorylation 
by orthovanadate. The pretreatment with a higher concentration of genistein (100 µM) 
decreased the orthovanadate-induced phosphorylation. Daidzein was clearly less effective 
(II). 
 
The two-day low-dose genistein treatment decreased tyrosine phosphorylation in the aortic 
rings. The two-week high-dose genistein treatment did not alter phosphorylation compared 
to the controls. The inhibitory effect of the low-dose genistein treatment on tyrosine 
phosphorylation disappeared when the two-week treatment was completed (V). 
 
In conclusion, genistein decreased tyrosine phosphorylation in the mesenteric and aortic 
rings in vitro and ex vivo, as well as in the cultured VSMCs. 
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6. DISCUSSION 
 
The protective role of estradiol-17β in cardiovascular diseases is well known, while the 
effects of genistein and daidzein and their possible mechanisms have not been so widely 
studied. In the present study, the effects of the plant-derived estrogens genistein and 
daidzein on arterial tone and blood pressure were investigated and compared to those of 
estradiol-17β. Normotensive male and female rats (Studies I, II, and III), ovariectomized 
normotensive female rats (Study III), male and female spontaneously hypertensive rats 
(Study IV), and ovariectomized spontaneously hypertensive rats (Study V) were used. The 
study evaluated in particular the role of gender, endothelium, potassium channels, 
estrogen receptors and tyrosine phosphorylation in genistein- and daidzein-induced 
arterial responses. 
 
6.1. Methodology 
 
The superior mesenteric artery of rats was used as a model of the resistance artery in all 
the experiments. The mesenteric artery is suitable for organ bath studies because it 
produces a stable precontraction and its diameter is about 1-1.5 mm, which allows its 
preparation without a light microscope. The renal artery was also studied in one 
experiment, because it regulates the perfusion of the kidney and in this way participates in 
the control of blood pressure. 
 
Plasma genistein and daidzein concentrations reach micromolar level after a soy-based 
meal in man (King & Bursill 1998) and in rat (King et al. 1996; King 1998). Thus, the 
concentrations of genistein and daidzein used in the present study to induce arterial 
relaxations in vitro, are physiologically achievable. On the contrary, the normal estradiol-
17β concentration in premenopausal woman is within the nanomolar range. In the present 
study the concentrations of estradiol-17β, genistein and daidzein needed to induce 
relaxation in vitro were micromolar. This phenomenon - that the effective in vitro 
concentration is far from physiological concentration - is often described in connection with 
estradiol-17β (Jiang et al. 1991; Mügge et al. 1993).  
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Because genistein and daidzein are ER agonists (Miksicek 1993), their hormonal effects 
were investigated. The serum estradiol-17β and testosterone concentrations of rats as well 
as the weights of the uteri, ovaries, and testes were measured, and the morphologis of the 
uteri were investigated. 
 
Wistar rats are normotensive rats, and are resistant to cardiovascular diseases. The 
mesenteric arteries of Wistar rats served as a model of an artery with normal functional 
structure, whereas the arteries of adult SHRs often have alterations in their structure and 
function caused by hypertension. A number of the Wistar rats and SHRs were 
ovariectomized in order to arrest the production of estrogens and to induce a 
“postmenopausal” state in the rats. A lack of estrogens causes the same state in rats as in 
humans osteoporosis for instance, (Arjmandi et al. 1998a; Arjmandi et al. 1998b), and 
elevated blood pressure (Hinojosa-Laborde et al. 2000). 
 
SHRs were studied because the SHR is a commonly used, and regarded as a good 
animal model of human essential hypertension. The SHR is an inbred strain, which 
develops hypertension and its complications with increasing age. Systolic blood pressure 
was measured by the tail cuff method, which has been reported to show good correlation 
to the recordings using intra-arterial catheters in rats (Bunag & Butterfield 1982). The main 
limitations are that diastolic blood pressure cannot be obtained and that the measurement 
cannot be carried out in freely moving animals. The variability of blood pressure values is 
also large, but this can be partly eliminated if only one person handles the animals and 
carries out the measurements in a peaceful environment. 
 
6.2. Endothelium- and estrogen-receptor-independent relaxations of estradiol-17β, 
genistein and daidzein 
 
Estradiol-17β, genistein and daidzein relaxed rat mesenteric arterial rings endothelium-
independently. It has been demonstrated that endothelium is not necessary for either 
female or male sex-hormone-induced relaxations in vitro. Estradiol-17β (Jiang et al. 1991), 
progesterone (Jiang et al. 1992) and testosterone (Yue et al. 1995) all relax arterial 
smooth muscle endothelium-independently. Genistein also relaxes rabbit coronaries 
endothelium-independently (Figtree et al. 2000). Although the relaxations caused by 
estradiol-17β, genistein and daidzein are not mediated via the endothelium in vitro, 
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endothelial cells do contain ERs (Kim-Schulze et al. 1996). Estradiol-17β increases the 
synthesis of PGI2 (Mikkola et al. 1996) and NO (Hayashi et al. 1995) ER-dependently, 
suggesting that the endothelium is a target for sex hormone action in some situations. 
 
Tamoxifen, an antagonist of ER, did not inhibit estradiol-17β- genistein- or daidzein-
induced relaxations. All these relaxations began about two to four minutes after the 
compound had been added to the organ bath chamber, which further supports the theory 
that acute hormone-induced relaxations in vitro are not mediated via ERs. Other 
investigators have achieved similar results: estradiol-17β (Jiang et al. 1991; Shaw et al. 
2000), genistein (Figtree et al. 2000; Mishra et al. 2000), and daidzein (Mishra et al. 2000) 
have been shown to induce vasodilation via a non-genomic mechanism. Moreover, 
estradiol-17α, which is a steroid, devoid of genomic estrogenic effects, is also able to relax 
arteries (Salas et al. 1994). All these results suggest that ERs are not involved in estradiol-
17β-, genistein- and daidzein-induced relaxations in vitro. However, both ERα and ERβ 
are expressed at least in the coronary arteries and in cultured aortic smooth muscle cells 
(Register & Adams 1998), suggesting that the VSMCs are targets of estrogen action. 
Estradiol-17β inhibits the proliferation of VSMCs ER-dependently (Cathapermal et al. 
1998), and the blocking of ERs induces VSMC proliferation (Lavigne et al. 1999). Thus, 
although ERs are not involved in the acute vasodilatory effect of estradiol-17β, genistein 
and daidzein, ERs are of importance in regulating the function of VSMC. 
 
6.3. Role of potassium channels in estradiol-17β-, genistein- and daidzein-induced 
relaxations 
 
Estradiol-17β-, genistein- and daidzein-induced relaxations were antagonized by IbTX, 
which is an inhibitor of large conductance KCa channels. This accords with the finding that 
in the rabbit coronary artery, estradiol-17β-induced relaxation is mediated via the KCa 
channels (White et al. 1995). The supposed mechanism of the interaction of estradiol-17β 
and the KCa channel is that estradiol-17β binds directly to the regulatory (β) subunit of the 
KCa channel and activates it (Valverde et al. 1999). This leads to the hyperpolarization and 
relaxation of smooth muscle. Whether genistein and daidzein bind similarly to KCa 
channels is still unclear. However, genistein, but not daidzein, has been shown to increase 
KCa channel currents in vascular smooth muscle (Xiong et al. 1995), and in trabecular 
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meshwork (Stumpff et al. 1999) cells. Thus, it is possible that genistein acts in the same 
way as estradiol-17β in activating KCa channels. 
 
In the present study, estradiol-17β-induced relaxation was reduced by IbTX, but not by 
ChTX, or by TEA, all of which antagonize large conductance KCa.channels. TEA, however, 
is an unspecific K+ channel blocker. Depending on the concentration used, it inhibits KCa, 
KATP, and KV channels (for review, see Nelson & Quayle 1995). TEA binds with moderate 
affinity to the external pore of the KCa channel (for review, see Kaczorowski et al. 1996). 
ChTX is a more selective inhibitor of this channel, but IbTX is even better (for review, see 
Kaczorowski et al. 1996). The dissociation rate of IbTX from the pore of the KCa channel is 
much slower than for ChTX (Candia et al. 1992). To sum up, IbTX is the most selective 
inhibitor of KCa channels, and therefore it is logical that it was the most potent inhibitor of 
the relaxations that were studied. 
 
Because IbTX inhibited the relaxation responses of estradiol-17β, genistein and daidzein, 
these relaxations seem to be mediated, at least partly, via KCa channels. However, in 
tracheal smooth muscle, IbTX decreases the relaxation response to salbutamol, but this 
inhibitory effect is totally reversed by nifedipine, (Huang et al. 1993), which is an 
antagonist of L-type voltage-dependent Ca2+ channels. This suggests that IbTX causes 
membrane depolarisation, which in turn activates voltage-dependent Ca2+ channels, and 
the influx of Ca2+ via these channels increases the arterial contraction level, which 
overcomes relaxation. This indicates that the antagonism produced by this toxin is 
functional and not at the level of the gating on KCa channels. On the other hand, it is typical 
for K+ channel openers, as for levcromakalim, that it cannot relax VSMCs in a K+-rich 
medium (Cook et al. 1995). In Study I, estradiol-17β, genistein and daidzein all relaxed 
mesenteric arterial rings precontracted by potassium chloride 60 mM, indicating that these 
substances are not pure K+ channel openers. Therefore, the possibility that the inhibitory 
effect of IbTX on the arterial relaxations induced by estradiol-17β, genistein and daidzein 
may be of a functional nature, cannot totally be excluded. 
 
Glibenclamide, a specific antagonist of the KATP channel, had no effect on the relaxations 
induced by estradiol-17β, genistein or daidzein, indicating that KATP channels do not play 
an important role in these responses. In porcine coronary arteries, glibenclamide does not 
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affect estradiol-17β-induced relaxations, either (White et al. 1995). On the other hand, KATP 
channels have been shown to mediate testosterone-induced relaxation responses in vivo 
in coronaries (Chou et al. 1996). Interestingly, it has been reported that in the coronary 
artery preparation in vitro, glibenclamide does not reduce the relaxation induced by 
testosterone (Yue et al. 1995). It is therefore possible that KATP channel inhibitors could 
alter estradiol-17β-, genistein- and daidzein-induced relaxations in in vivo models. On the 
other hand, genistein inhibits, and does not activate, KATP channels in the rabbit portal vein 
smooth muscle in vitro (Ogata et al. 1997), which indicates differences between arterial 
and venous smooth muscles in the function of KATP channels. 
 
Clearly, estradiol-17β, genistein and daidzein are not pure K+ channel openers. Therefore, 
other relaxing mechanisms are likely to exist. It has been suggested that estradiol-17β 
relaxes arteries by blocking Ca2+ channels (Collins et al. 1993). In isolated VSMCs, 
pharmacological (0.1-10 µM) concentrations of estradiol-17β inhibit L-type Ca2+ channel 
currents (Kitazawa et al. 1997). Genistein (Figtree et al. 2000) and some estrogenic 
pollutants (Ruehlmann et al. 1998) have been shown to relax VSMCs by blocking L-type 
Ca2+ channels. Genistein also reduces voltage dependent Ca2+ currents in VSMCs 
(Wijetunge et al. 1992), and daidzein is almost as effective as genistein in inhibiting L-type 
Ca2+ channels in ventricular cells (Yokoshiki et al. 1996). To sum up, it is possible that part 
of the relaxation caused by estradiol-17β, genistein and daidzein is due to the inhibition of 
L-type Ca2+ channels. 
 
6.4. Role of tyrosine kinase inhibition of genistein in arterial responses 
 
Apart from being an estrogen agonist, genistein is also a tyrosine kinase inhibitor (Akiyama 
et al. 1987), whereas daidzein is inactive in this respect. Tyrosine kinase inhibitors 
attenuate arterial contractions to many substances (for review, see Hughes & Wijetunge 
1998). Sodium orthovanadate, which increases tyrosine phosphorylation (Laniyonu et al. 
1994), on the other hand, induces contraction in VSMCs (Shimada et al. 1986). In Studies 
I and II, genistein was a slightly more effective relaxant than daidzein. In Study II, genistein 
inhibited more tyrosine phosphorylation than daidzein, both in the mesenteric arterial rings 
and in the cultured aortic VSMCs. The greater relaxing capacity of genistein than daidzein 
suggests that part of the relaxing property of genistein may be due to the decreased level 
of tyrosine phosphorylation in VSMCs, but this may not be the only mechanism. 
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In Study V, the two-day low-dose genistein treatment attenuated renal arterial contractility 
to all the contracting compounds tested in OVX SHRs. Tyrosine phosphorylation was 
reduced in aortic smooth muscle by the two-day genistein treatment, whereas neither the 
two-day treatment of estradiol-17β nor the high-dose genistein treatments reduced the 
phosphorylation level. Other investigators have shown that genistein reduces renal 
vascular resistance (Giménez et al. 1998). Genistein and other tyrosine kinase inhibitors 
antagonize the increase of [Ca2+] inside the VSMCs reversibly (for review, see Di Salvo et 
al. 1997). They also regulate the effect of Ca2+ on the contractile apparatus of VSMCs 
(Toma et al. 1995). Because of these effects both the depolarization and the contraction of 
VSMCs are antagonized. Thus, genistein inhibits tyrosine kinase and in this way modifies 
renal arterial contractility. 
 
It is interesting that the renal arterial contractions and aortic smooth muscle tyrosine 
phosphorylation were unaffected by the two-day high-dose (25 mg/kg) genistein treatment. 
The tyrosine kinase inhibitor activity of genistein is evident at high doses (up to 1mg/kg) 
(Akiyama et al. 1987). Our results suggest that at very high doses genistein loses its 
specificity to inhibit tyrosine kinase. The decreasing effect of the low-dose genistein 
treatment on renal arterial contractions and tyrosine phosphorylation disappeared after the 
two-week treatment. It is possible that tyrosine phosphorylation is compensatorily 
increased after the drop of the basal level during the first days of a genistein treatment. 
 
6.5. Effect of male gender and ovariectomy on mesenteric arterial responses ex 
vivo 
 
Male gender and OVX increased mesenteric arterial contractility compared to normal 
female rats in both a receptor and a depolarization mediated way. Other researchers have 
shown that estradiol-17β inhibits VSMC proliferation ER-dependently in female rats 
(Espinosa et al. 1996) and in pigs (Vargas et al. 1993). Estradiol-17β also activates a 
cAMP-adenosine pathway in VSMCs, which inhibits growth (Dubey et al. 2000). Thus, the 
lack of estrogens in male and OVX rats can enhance arterial contractility by increasing 
VSMC mass, which increases the force of the contractions. 
 
Noradrenaline activates adrenergic α1 and α2 receptors. The absence or presence of 
estrogen modifies the receptor density of VSMCs. ERT reduces the density of α2 receptors 
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in OVX rat arteries (Gisclard et al. 1987) and suppresses α1 receptor expression in OVX 
rat VSMCs (Zhang & Davidge 1999). However, testosterone stimulates the expression of 
α1 receptors in VSMCs (Philippe et al. 1991). Therefore, the increased contractions to 
noradrenaline in male and OVX female rats in the present study may be the result of 
altered α1 and α2 receptor densities. 
 
One possible explanation for increased depolarization mediated contractility in male and 
OVX rats might be the difference in the Ca2+ influx of VSMCs. It has been reported that in 
male SHRs, the Ca2+ entry in VSMCs is greater than in their female counterparts (Crews 
et al. 1999). OVX in female rats, however, raises the Ca2+ influx to the level of male SHRs 
(Crews et al. 1999). It has also been suggested that estradiol-17β directly blocks Ca2+ 
channels and in this way inhibits depolarization (Collins et al. 1993). 
 
6.6. Endothelium-dependent relaxations 
 
In Study III, neither male gender nor OVX modified the endothelium-dependent 
relaxations. It has been reported that both gender and OVX alter the function of the 
endothelium. The basal release of NO is greater from the aortic rings of female rabbits 
than from those of male rabbits (Hayashi et al. 1992). OVX, however, diminishes the basal 
release to levels seen in male rabbits (Hayashi et al. 1992). In SHRs, OVX lowers both 
basal and shear stress-induced NO production (Huang et al. 1998). In this study, 
normotensive rats were used, which can partly explain the normal endothelium function. 
 
The five-week soy protein supplementation in Study IV and the two-week genistein and 
estradiol-17β treatments in Study V, had no effect on the endothelium-dependent 
relaxations in SHRs. However, other investigators have shown that an oral genistein 
supplementation of four to five weeks improves endothelium-dependent relaxations in 
OVX rats (Squadrito et al. 2000). Estradiol-17β has a similar effect. An ERT of twelve 
weeks enhances endothelium-dependent relaxations in SHRs (Williams et al. 1988). The 
improved endothelial function is associated with the maintainance of NO synthesis by 
estrogen in the arterioles of OVX hypertensive rats (Huang et al. 1997). In Studies IV and 
V, the rats were still young at the end of the experiment and the treatment times were 
obviously too short to be able to affect the function of the endothelium. 
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6.7. Blood pressure 
 
The soy protein supplementation, rich in genistein and daidzein, attenuated the 
development of hypertension in SHRs compared to the casein supplementation. Whether 
a soy-based diet could decrease blood pressure when hypertension has already 
developed was long time unclear. Quite recently, it has been shown that soy protein 
contains peptides, which inhibit ACE and thereby reduce blood pressure in SHRs (Wu & 
Ding 2001). 
 
The protein source and the total amount may be important in the regulation of blood 
pressure. Epidemiological studies suggest an inverse relationship between dietary protein 
intake and blood pressure, but published intervention trials do not support this hypothesis 
(for review, see Nurminen et al. 1998). In Study IV the total protein content of the soy 
protein used was 90% and the total protein content of casein was 86%, and the total 
protein contents of soy-based and casein-based diets were 18% and 17% respectively. 
This difference is too small to explain the lower blood pressure in SHRs on soy-based diet. 
 
In monozygotic twins, a direct association of dietary protein intake and diastolic blood 
pressure has been described; the more protein-rich their diet, the greater the increase in 
their diastolic blood pressure (Havlik et al. 1990). In Study IV, only systolic blood pressure 
was measured. Therefore the relationship between protein supplementation and diastolic 
blood pressure remains to be clarified. Although dietary casein, an animal protein derived 
from milk, accelerated the development of hypertension in SHRs in Study IV, its effect is 
not always detrimental to experimental hypertension. A casein-rich diet has been found to 
attenuate the development of severe hypertension in stroke-prone SHRs (Ikeda et al. 
1987).  
 
The soy protein used in Study IV, contained genistein and daidzein. In Study I and II we 
showed that genistein and daidzein relaxed arterial smooth muscle endothelium-
indepedently. Peripheral arterial resistance regulates blood pressure. It is possible that 
genistein and daidzein reduce peripheral resistance and thus attenuate the development 
of hypertension. 
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Two-week treatments with estradiol-17β, or low- or high-dose genistein treatments did not 
prevent the development of hypertension in OVX SHRs. However, in the normal SHRs, 
ERT of nine weeks (Hoeg et al. 1977) or seven months (Iams & Wexler 1979) lowers 
blood pressure. In OVX female SHRs, an ERT of seven months attenuates the 
development of hypertension (Iams & Wexler 1979). In the present study, the blood 
pressure was unaffected, probably because of the relatively short treatment time. 
 
To sum up, a soy protein diet protects against the development of hypertension, whereas 
casein is not beneficial in this respect in SHRs. However, it is not yet clear which 
component of the soy is the most important in the protection against high blood pressure. 
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7. CONCLUSIONS 
 
The aim of the present study was to investigate the effects of the plant-derived estrogens 
genistein and daidzein on arterial tone and on blood pressure, and to compare their effects 
to those of estradiol-17β. The major findings and conclusions are as follows: 
 
1. Genistein, daidzein and estradiol-17β relaxed arteries. Estradiol-17β was the most 
potent relaxant, and daidzein was the weakest. 
2. Although genistein and daidzein bind to estrogen receptors (ER) and activate them, 
their relaxing effect on arteries was independent of the ERs. The relaxations were also 
independent of gender and the endothelium. These relaxations were mediated, at least 
partly, via KCa-channels, and this mechanism resembled that of estradiol-17β. 
3. Genistein, but not daidzein, reduced tyrosine phosphorylation in the arterial rings and in 
cultured vascular smooth muscle cells, suggesting that the slightly more potent relaxing 
effect of genistein than daidzein may due to tyrosine kinase inhibition. 
4. Male gender and ovariectomy increased the contractility of the resistance artery, which 
may be one risk factor of cardiovascular diseases in males and postmenopausal 
females. 
5. Soy protein, rich in genistein and daidzein, attenuated the development of hypertension 
in spontaneously hypertensive rats compared to a casein-based diet. This indicates 
that the replacement of milk protein by soy protein may have a beneficial influence on 
blood pressure. 
6. The two-day low-dose genistein treatment reduced the contractility of the renal arteries 
and the tyrosine phosphorylation of the arterial smooth muscle. Both these effects 
disappeared after the two-week genistein treatment. 
 
In conclusion, the plant-derived estrogens genistein and daidzein relax arterial smooth 
muscle in a similar way as estradiol-17β in rat in vitro. These relaxations are related to the 
activation of KCa channels, but are independent of endothelium, ERs and gender. The 
tyrosine kinase inbition by genistein also have a role in genistein-induced arterial 
relaxations. In addition, the soy protein has a beneficial effect on blood pressure. The 
present experimental findings agree with the epidemiological data, but controlled 
intervention studies are needed to verify these observations. 
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